{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:56:35Z","timestamp":1790873795424,"version":"4.1.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research Foundation \u2013 Flanders","award":["12X9420N"],"award-info":[{"award-number":["12X9420N"]}]},{"name":"IBD Patient\u2019s Association Flanders"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Adequate infliximab concentrations during induction treatment are predictive for deep remission [corticosteroid-free clinical and endoscopic remission] at 6 months in children with inflammatory bowel diseases [IBD]. Under standard infliximab induction dosing, children often have low infliximab trough concentrations. Model-informed precision dosing [MIPD; i.e. model-based therapeutic drug monitoring] is advocated as a promising infliximab dosing strategy. We aimed to develop and validate an MIPD framework for guiding paediatric infliximab induction treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 31 children with IBD [4\u201318 years] receiving standard infliximab induction dosing (5 mg\/kg at week [w]0, w2 and w6) were repurposed. Eight paediatric population pharmacokinetic models were evaluated. Modelling and simulation were used to identify exposure targets, identify an optimal sampling strategy, and develop a multi-model prediction algorithm for implementation into an MIPD software tool. A role for infliximab clearance monitoring was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 7.5 mg\/L infliximab concentration target at w12 was associated with 64% probability of deep remission at 6 months. With standard dosing, less than 80% of simulated children &amp;lt;40 kg attained this target. The w12 target was most accurately and precisely achieved by implementing MIPD at w6 using the w6 infliximab concentration [rapid assay required]. The multi-model algorithm outperformed single models when optimizing the w6 dose based on both w2 and w4 concentrations. MIPD using only the w2 concentration resulted in biased and imprecise predictions. Infliximab clearances at w6 and w12 were predictive for deep remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A freely available, multi-model MIPD tool facilitates infliximab induction dosing and improves deep remission rates in children with IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad009","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T23:42:36Z","timestamp":1674085356000},"page":"896-908","source":"Crossref","is-referenced-by-count":28,"title":["A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9285-799X","authenticated-orcid":false,"given":"Wannee","family":"Kantasiripitak","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, University of Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G","family":"Wicha","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-9846","authenticated-orcid":false,"given":"Debby","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, University of Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Hepatology, and Nutrition, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven , Belgium"},{"name":"Department of Chronic Diseases and Metabolism, University of Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven , Belgium"},{"name":"Department of Chronic Diseases and Metabolism, University of Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"van Hoeve","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Hepatology, and Nutrition, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, University of Leuven , Leuven , Belgium"},{"name":"Department of Bioengineering and Therapeutic Sciences, University of California , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"2023061613195099300_CIT0001","volume-title":"Remicade: EPAR - Product Information;","author":"Janssen Biologics B.V","year":"2021"},{"key":"2023061613195099300_CIT0002","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"2023061613195099300_CIT0003","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/01.MIB.0000435438.84365.f7","article-title":"Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study","volume":"19","author":"Adedokun","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0004","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"2023061613195099300_CIT0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MPG.0000000000002265","article-title":"Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease","volume":"68","author":"van Hoeve","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613195099300_CIT0006","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpeds.2021.08.079","article-title":"Infliximab concentrations during induction are predictive for endoscopic remission in pediatric patients with inflammatory bowel disease under combination therapy","volume":"240","author":"van Hoeve","year":"2022","journal-title":"J Pediatr"},{"key":"2023061613195099300_CIT0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN Guideline Update","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023061613195099300_CIT0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MPG.0000000000002304","article-title":"Development of infliximab target concentrations during induction in pediatric Crohn disease patients","volume":"69","author":"Clarkston","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613195099300_CIT0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care \u2013 an evidence-based guideline from European Crohn\u2019s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613195099300_CIT0011","first-page":"48","article-title":"Therapeutic drug monitoring in children and young adults with inflammatory bowel disease: a practical approach","volume":"11","author":"Singh","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"2023061613195099300_CIT0012","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"2023061613195099300_CIT0013","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease","volume":"154","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology"},{"key":"2023061613195099300_CIT0014","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"2023061613195099300_CIT0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased \u00adclinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology"},{"key":"2023061613195099300_CIT0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"2023061613195099300_CIT0017","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","article-title":"pharmacokinetics, pharmacodynamics and immunogenicity of infliximab in paediatric inflammatory bowel disease; a systematic review and revised dosing considerations","volume":"70","author":"Winter","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613195099300_CIT0018","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2174\/0929867324666170911163021","article-title":"Therapeutic drug monitoring in pediatric IBD: current application and future perspectives","volume":"25","author":"Lega","year":"2018","journal-title":"Curr Med Chem"},{"key":"2023061613195099300_CIT0019","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol"},{"key":"2023061613195099300_CIT0020","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2014.12.010","article-title":"A novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine","volume":"45","author":"Wicha","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2023061613195099300_CIT0021","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1097\/MIB.0000000000000434","article-title":"An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases","volume":"21","author":"Van Stappen","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0022","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohn\u2019s disease activity index","volume":"12","author":"Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613195099300_CIT0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"2023061613195099300_CIT0024","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"2023061613195099300_CIT0025","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","article-title":"IOIBD technical review on endoscopic indices for Crohn\u2019s disease clinical trials","volume":"65","author":"Vuitton","year":"2016","journal-title":"Gut"},{"key":"2023061613195099300_CIT0026","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.13948","article-title":"Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus","volume":"45","author":"Vuitton","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613195099300_CIT0027","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2023061613195099300_CIT0028","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/ajg.2010.143","article-title":"Appraisal of the pediatric Crohn\u2019s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties","volume":"105","author":"Turner","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2023061613195099300_CIT0029","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/ibd.20867","article-title":"Appraisal of the pediatric ulcerative colitis activity index (PUCAI)","volume":"15","author":"Turner","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0030","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2023061613195099300_CIT0031","volume-title":"ubiquity: PKPD, PBPK, and Systems Pharmacology Modeling Tools"},{"key":"2023061613195099300_CIT0032","volume-title":"epitools: Tools for training and practicing epidemiologists including methods for twoway and multi-way contingency tables"},{"key":"2023061613195099300_CIT0033","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): A model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm Res"},{"key":"2023061613195099300_CIT0034","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","article-title":"Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide","volume":"23","author":"Brendel","year":"2006","journal-title":"Pharm Res"},{"key":"2023061613195099300_CIT0035","volume-title":"dmutate: Mutate Data Frames with Random Variates"},{"key":"2023061613195099300_CIT0036","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cpt.2065","article-title":"A model averaging\/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study","volume":"109","author":"Uster","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2023061613195099300_CIT0037","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/psp4.12813","article-title":"Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases","volume":"11","author":"Kantasiripitak","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2023061613195099300_CIT0038","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/MCG.0000000000000884","article-title":"CRP\/albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis","volume":"52","author":"Gibson","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"2023061613195099300_CIT0039","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/ibd\/izy129","article-title":"Modeling immunization to infliximab in children with Crohn\u2019s disease using population pharmacokinetics: a pilot study","volume":"24","author":"Petitcollin","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0040","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","article-title":"The underlying inflammatory chronic disease influences infliximab pharmacokinetics","volume":"8","author":"Passot","year":"2016","journal-title":"MAbs"},{"key":"2023061613195099300_CIT0041","author":"Clinical Growth Charts.","year":"2022"},{"key":"2023061613195099300_CIT0042","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1208\/s12248-017-0082-8","article-title":"Foster DJR. infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies","volume":"19","author":"Wojciechowski","year":"2017","journal-title":"AAPS J"},{"key":"2023061613195099300_CIT0043","first-page":"izab285","article-title":"Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity","author":"Dubinsky","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0044","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/MPG.0000000000002410","article-title":"Determination of serum infliximab concentration by point-of-care devices in children with inflammatory bowel disease","volume":"69","author":"Curci","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613195099300_CIT0045","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/ibd.22902","article-title":"Doubling the infliximab dose versus halving the infusion intervals in Crohn\u2019s disease patients with loss of response","volume":"18","author":"Katz","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0046","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ibd.21886","article-title":"Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn\u2019s disease","volume":"18","author":"Hibi","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0047","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0000000000001302","article-title":"Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"64","author":"Hofmekler","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613195099300_CIT0048","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ecco-jcc\/jju026","article-title":"High-dose infliximab therapy in Crohn\u2019s disease: clinical experience, safety, and efficacy","volume":"9","author":"Hendler","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2023061613195099300_CIT0049","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023061613195099300_CIT0050","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/ibd\/izy132","article-title":"Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn\u2019s disease","volume":"24","author":"Papamichael","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613195099300_CIT0051","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2023061613195099300_CIT0052","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn\u2019s disease","volume":"109","author":"Xiong","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2023061613195099300_CIT0053","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bcp.14364","article-title":"Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn\u2019s disease","volume":"87","author":"Dreesen","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2023061613195099300_CIT0054","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1208\/s12248-016-9994-y","article-title":"Pharmacokinetic dashboard-recommended dosing is different than standard of care dosing in infliximab-treated pediatric IBD patients","volume":"19","author":"Dubinsky","year":"2017","journal-title":"AAPS J"},{"key":"2023061613195099300_CIT0055","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1002\/jcph.1829","article-title":"Pediatric dose selection for therapeutic proteins","volume":"61","author":"Malik","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2023061613195099300_CIT0056","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/jcph.1677","article-title":"Model-aided adults-to-children pharmacokinetic extrapolation and empirical body size-based dosing exploration for therapeutic monoclonal antibodies-is allometry a reasonable choice?","volume":"60","author":"Xu","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2023061613195099300_CIT0057","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/jcph.1830","article-title":"Status toward the implementation of precision dosing in children","volume":"61","author":"Barrett","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2023061613195099300_CIT0058","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cpt.1429","article-title":"Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases","volume":"106","author":"Petitcollin","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2023061613195099300_CIT0059","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/17512433.2021.2028619","article-title":"Recent advancements in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases","volume":"14","author":"Kantasiripitak","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2023061613195099300_CIT0060","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023061613195099300_CIT0061","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023061613195099300_CIT0062","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad009\/49244972\/jjad009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/6\/896\/50627691\/jjad009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/6\/896\/50627691\/jjad009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T09:21:15Z","timestamp":1686907275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/6\/896\/6994181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,1,20]]},"published-print":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad009","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,1,20]]}}}